BCDA Form 4: Peter Altman purchases 400 shares at $1.751 avg

Rhea-AI Filing Summary

Peter Altman, who serves as President and CEO and is a director of BioCardia, Inc. (BCDA), reported a purchase of 400 shares of the issuer's common stock on 08/12/2025. The trades were executed in multiple fills between $1.70 and $1.83 per share, with a weighted average price of $1.751 per share. After this activity, his direct beneficial ownership is reported as 167,962 shares. The filer notes they can provide per-trade quantities and prices upon request.

Positive

• Insider purchase disclosed: The reporting person acquired 400 shares at a weighted average price of $1.751, increasing direct holdings to 167,962 shares.
• Transparent pricing range: The filing specifies the transaction range of $1.70 to $1.83 and offers to provide per-trade details on request.

Negative

• None.

Insights

Financial Analyst

TL;DR Insider purchase of 400 shares at a $1.751 weighted average increases direct holdings to 167,962 shares; size is small relative to total holdings.

The reported acquisition is factual and straightforward: 400 common shares were purchased in multiple trades at prices ranging from $1.70 to $1.83, producing a weighted average price of $1.751. The purchase raises the reporting person’s direct stake to 167,962 shares. From a market-impact perspective, the transaction size is modest versus the total reported holdings, so it is unlikely to materially change control or valuation metrics, though it does represent an executive-level purchase of the company’s stock.

Corporate Governance Expert

TL;DR Form 4 documents a routine executive purchase with clear disclosure of price range and aggregate holdings; procedural compliance appears satisfied.

The filing discloses an insider purchase executed via multiple trades and provides a weighted average price and the reported post-transaction direct ownership. The explanatory note commits to provide per-trade details on request, which supports transparency. There are no indications in this Form 4 of derivative transactions, dispositions, or changes in beneficial ownership form that would raise governance concerns.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Altman Peter

(Last) (First) (Middle)

C/O BIOCARDIA, INC.

320 SOQUEL WAY

(Street)

SUNNYVALE CA 94085

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BioCardia, Inc. [ BCDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/12/2025		P		400(1)	A	$1.751(1)	167,962	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades ranging from $1.70 to $1.83 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.

	/s/ David McClung, by power of attorney	08/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 4 filed for BioCardia (BCDA) report?

The Form 4 reports that Peter Altman purchased 400 shares of common stock on 08/12/2025, bringing his direct holdings to 167,962 shares.

At what price were the BioCardia shares purchased on the Form 4?

The trades occurred between $1.70 and $1.83 per share, with a weighted average price of $1.751 per share.

Does the Form 4 indicate whether the purchase was a single trade or multiple trades?

The filing states the transaction was executed in multiple trades and that the reporting person can provide detailed per-trade information upon request.

How much did the reporting person's ownership change after the reported transaction?

Following the reported acquisition, the reporting person’s direct beneficial ownership is listed as 167,962 shares.

Were any derivative securities reported in this Form 4 for BioCardia?

No derivative securities are reported in Table II; only a non-derivative common stock purchase is disclosed in Table I.